ClinicalTrials.gg
CompletedNCT07334860Updated Jun 15, 2026

A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011)

A Phase 1 interventional study of MK-1167 in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Researchers are looking for new ways to treat Alzheimer's disease (AD). AD is a brain disease that causes a gradual decline in memory, thinking, and ability to carry out daily tasks. MK-1167 is a study medicine designed to treat symptoms of AD. Before giving a study medicine to people with a health condition, researchers first do studies in healthy people to find a safe dose of the study medicine.

The goals of the trial are to learn:

  • What happens to different forms of MK-1167 in a healthy person's body over time
  • About the safety of MK-1167 and if people tolerate it
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is in good health
  • Has a (BMI) ≥18 and ≤ 32 kg/m\^2, inclusive

Exclusion criteria

Exclusion Criteria:

  • Has a history of endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
  • Is a smoker and/or has used nicotine or nicotine-containing products within the past 3 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Arm 1: MK-1167 Form 2

    Participants receive MK-1167 Form 2 orally.

    Drug: MK-1167

  • Experimental
    Arm 2: MK-1167 Form 1

    Participants receive MK-1167 Form 1 orally.

    Drug: MK-1167

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve from Time 0 to Infinity (AUC0-inf) of MK-1167

    Blood samples will be collected to determine the AUC0-inf of MK-1167.

    Time frame: At designated time points (up to approximately 21 days)

  2. Maximum Plasma Concentration (Cmax) of MK-1167

    Blood samples will be collected to determine the Cmax of MK-1167.

    Time frame: At designated time points (up to approximately 21 days)

  3. Area Under the Curve from Time 0 to Last Measurable Concentration (AUC0-last) of MK-1167

    Blood samples will be collected to determine the AUC0-last of MK-1167.

    Time frame: At designated time points (up to approximately 21 days)

Secondary outcomes

  1. Area Under the Curve from Time 0 to 24 hours (AUC0-24) of MK-1167

    Blood samples will be collected to determine the AUC0-24 of MK-1167.

    Time frame: At designated time points (up to approximately 24 hours)

  2. Concentration at 24 hours (C24) of MK-1167

    Blood samples will be collected to determine the C24 of MK-1167.

    Time frame: At designated time points (up to approximately 24 hours)

  3. Time to Maximum Serum Concentration (Tmax) of MK-1167

    Blood samples will be collected to determine the Tmax of MK-1167.

    Time frame: At designated time points (up to approximately 21 days)

  4. Apparent Terminal Half-life (t1/2) of MK-1167

    Blood samples will be collected to determine the t1/2 of MK-1167.

    Time frame: At designated time points (up to approximately 21 days)

  5. Apparent Clearance after Nonintravenous Administration (CL/F) of MK-1167

    Blood samples will be collected to determine the CL/F of MK-1167.

    Time frame: At designated time points (up to approximately 21 days)

  6. Apparent Volume of Distribution during Terminal Phase (Vz/F) of MK-1167

    Blood samples will be collected to determine the Vz/F of MK-1167.

    Time frame: At designated time points (up to approximately 21 days)

  7. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 78 days

  8. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 36 days

07

Study locations

1 site
  • QPS-MRA, LLC ( Site 0001)
    South Miami, Florida 33143, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in May 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2025
First posted
Jan 12, 2026
StartActual
Feb 6, 2026
Primary completionActual
May 20, 2026
CompletionActual
May 20, 2026
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07334860
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Feb 6, 2026
Primary completion
May 20, 2026
Completion
May 20, 2026
Last update
Jun 15, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-1167

Start the discussion